Is retatrutide more effective than tirzepatide?

Its reported figures are higher, but from separate trials with different populations and durations. TRIUMPH-5 tests it directly, completing November 2026.

Does more receptors always mean better tolerated?

No, generally the opposite. Though SURMOUNT-5 found tirzepatide better tolerated than semaglutide on GI discontinuation, so it is not a strict rule.

Is retatrutide better than Mounjaro?

Mounjaro is tirzepatide. Retatrutide's reported 28.3% at 80 weeks is higher than tirzepatide's 20.2% in SURMOUNT-5, but those are different trials with different populations and durations, so the gap is not established. TRIUMPH-5 compares them directly and completes in November 2026.

Is retatrutide the same as Ozempic?

No. Ozempic is semaglutide, a GLP-1 agonist that has been licensed since 2017. Retatrutide is a different molecule engaging three receptors, and it holds no marketing authorisation anywhere.

Is retatrutide better than semaglutide?

Semaglutide is the molecule in Ozempic and Wegovy. Retatrutide's reported reductions are larger, but semaglutide's come from separate trials and semaglutide is licensed while retatrutide is not. No trial has compared the two directly.

Is retatrutide stronger than Mounjaro?

On reported weight reduction the retatrutide figures are higher, but no head-to-head trial has reported. Tolerability moves the other way: TRIUMPH-1 reported 11.3% discontinuation for adverse events on the 12 mg arm.

Retatrutide vs Mounjaro and Ozempic Compared

The short answer

Ozempic and Wegovy are semaglutide, which engages GLP-1. Mounjaro and Zepbound are tirzepatide, which adds GIP. Retatrutide adds glucagon on top and has no brand name because it is approved nowhere. Reported reductions rise across the three, but come from separate trials, so the comparison is indirect.

Key facts

Ozempic / Wegovy: Semaglutide; GLP-1 only; approved
Mounjaro / Zepbound: Tirzepatide; GIP + GLP-1; approved
Retatrutide: All three receptors; no brand name
SURMOUNT-5 head-to-head: Tirz 20.2% vs sema 13.7%
TRIUMPH-1: 28.3% at 80 weeks (12 mg)
Direct comparison: TRIUMPH-5, completing Nov 2026

Mounjaro, Ozempic, Wegovy: which name is which molecule

Mounjaro and Zepbound are the same molecule (tirzepatide) licensed under two names, the first for type 2 diabetes and the second for weight management. Ozempic and Wegovy are semaglutide, split along the same line. Retatrutide has no brand name at all, because a brand name is something a medicine acquires at approval and retatrutide is approved nowhere; in the literature it is LY3437943. So "retatrutide vs Mounjaro" is retatrutide against tirzepatide, and "retatrutide vs Ozempic" is retatrutide against semaglutide. The comparisons below use the molecule names for that reason.

The one comparison that is direct

SURMOUNT-5 randomised 751 adults to tirzepatide or semaglutide for 72 weeks: 20.2% against 13.7%. Same population, same duration, same trial. That is the strongest form of evidence and it establishes the dual agonist's advantage over the single one.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

The comparison that is not

Retatrutide's 28.3% comes from TRIUMPH-1 at 80 weeks; tirzepatide's figures come from SURMOUNT trials at 72. Different populations, different durations, and estimands that may differ. Placing 28.3% next to 20.9% suggests a precision the data does not support. The direction is probably right, the magnitude of the gap is not established.

What will settle it

TRIUMPH-5, registered as NCT06662383, randomises 800 adults to retatrutide or tirzepatide directly, with primary completion in November 2026. Because both are Lilly molecules on modified GIP scaffolds, it isolates the glucagon arm's contribution about as cleanly as a trial can.

The regulatory difference that matters most

Semaglutide and tirzepatide are licensed medicines with marketing authorisations. Retatrutide is investigational and approved nowhere; Lilly has signalled an FDA filing for Q1 2027. Comparing effect sizes across the three obscures the fact that two can be prescribed and one cannot.

Tolerability moves too

More receptors has consistently meant more gastrointestinal burden. TRIUMPH-1 reported 11.3% discontinuation due to adverse events on the 12 mg arm against 4.9% on placebo. SURMOUNT-5 reported the opposite pattern between its two arms (tirzepatide better tolerated than semaglutide on GI discontinuation) so the relationship is not perfectly monotonic.

And none of this concerns research material

Semaglutide and tirzepatide are prescription medicines. Retatrutide is an investigational compound in registered trials. Material supplied for laboratory research is not related to any of them, is not an alternative to any of them, and none of these figures describes it.

Quick reference

	Ozempic / Wegovy	Mounjaro / Zepbound	Retatrutide
Molecule	Semaglutide	Tirzepatide	LY3437943
Receptors	GLP-1	GIP + GLP-1	GIP + GLP-1 + glucagon
Molecular weight	4,114 Da	4,813 Da	~4,731 Da
Status	Approved	Approved	Investigational
Head-to-head	13.7% (SURMOUNT-5)	20.2% (SURMOUNT-5)	TRIUMPH-5 pending

Frequently asked questions

Is retatrutide more effective than tirzepatide?: Its reported figures are higher, but from separate trials with different populations and durations. TRIUMPH-5 tests it directly, completing November 2026.
Which can actually be prescribed?: Semaglutide and tirzepatide hold marketing authorisations. Retatrutide is investigational and approved nowhere.
Does more receptors always mean better tolerated?: No, generally the opposite. Though SURMOUNT-5 found tirzepatide better tolerated than semaglutide on GI discontinuation, so it is not a strict rule.
Is retatrutide better than Mounjaro?: Mounjaro is tirzepatide. Retatrutide's reported 28.3% at 80 weeks is higher than tirzepatide's 20.2% in SURMOUNT-5, but those are different trials with different populations and durations, so the gap is not established. TRIUMPH-5 compares them directly and completes in November 2026.
Is retatrutide the same as Ozempic?: No. Ozempic is semaglutide, a GLP-1 agonist that has been licensed since 2017. Retatrutide is a different molecule engaging three receptors, and it holds no marketing authorisation anywhere.
Is retatrutide better than semaglutide?: Semaglutide is the molecule in Ozempic and Wegovy. Retatrutide's reported reductions are larger, but semaglutide's come from separate trials and semaglutide is licensed while retatrutide is not. No trial has compared the two directly.
Is retatrutide stronger than Mounjaro?: On reported weight reduction the retatrutide figures are higher, but no head-to-head trial has reported. Tolerability moves the other way: TRIUMPH-1 reported 11.3% discontinuation for adverse events on the 12 mg arm.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Retatrutide vs Mounjaro, Ozempic and Wegovy